Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

ABSTRACT: Barcoded clones of T-47D cells were treated with either giredestrant, palbociclib, or their combination for different duration. Barcodes and transcriptional profiles was measured by scRNA-seq.

ORGANISM(S): Homo sapiens

PROVIDER: GSE260703 | GEO | 2025/01/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

Project description:T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

| PRJNA1082726 | ENA

ATACseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

2026-02-13 | GSE295128 | GEO

RNAseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

2026-02-13 | GSE295127 | GEO

Transcriptome modulation by long duration giredestrant treatment and the effect of GPX4 CRISPR KO in MCF7 cells

Project description:In the giredestrant resistance/sensitization CRISPR Ko whole genome screen in MCF7 cells, ferroptosis regulator GPX4 comes out as top sensitization hits. We like to see how GPX4 KO changes gene expression profiles, and how giredestrant alone and the combination of GPX4 KO and giredestrant long duration treatment modulate the transcriptome

2024-08-07 | GSE260702 | GEO

RNA-seq of human breast cancer cell lines MCF7 and T74D naive and resistant to palbociclib treated with capivasertib, fulvestrant and combination

Project description:T47D and MCF7 cell lines were treated with long-term (continuous) palbociclib to induce 4 resistant cell-lines (T47D RB-, T47D CDK6H, MCF7 RB- and MCF7 PacqR). Each cell line (both parental and resistant) were then treated with DMSO (control), capivasertib monotherapy, fulvestrant monotherapy and capivasertib/fulvestrant combination. RNA data is available after each treatment and resistant cell lines additionally have RNA data available after continuous palbociclib treatment.

2023-08-14 | E-MTAB-13262 | biostudies-arrayexpress

RNAseq analysis of taxol and palbociclib combination in pancreatic cancer

Project description:RNAseq from pancreatic cancer cell lines treated with DMSO, taxol, palbociclib or the combination at short-term time-points.

2020-02-06 | GSE135215 | GEO

FOXA1/FOXM1 ChIP-seq on giredestrant-resistant ER+ breast cancer cell lines

Project description:Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

2026-02-13 | GSE305432 | GEO

Inhibition of CDK6 using Palbociclib in combination with Ruxolitinib markedly improves myelofibrosis in murine models

Project description:Myelofibrosis (MF) is a deadly blood neoplasia that presents the worst prognosis among myeloproliferative neoplasms (MPN). Expression of CDK6 is significantly elevated in MPN/MF hematopoietic progenitor cells. In this study, we investigated the efficacy of CDK4/6 inhibitor Palbociclib alone or in combination with Ruxolitinib in Jak2V617F and MPLW515L murine models of MF. Treatment of Palbociclib alone significantly reduced leukocytosis, splenomegaly and inhibited bone marrow fibrosis in Jak2V617F and MPLW515L mouse models of MF. Combined treatment of Palbociclib and Ruxolitinib resulted in normalization of peripheral blood leukocyte counts, marked reduction of spleen size and abrogation of bone marrow fibrosis in murine models of MF. Mechanistically, we show that Palbociclib treatment or depletion of CDK6 inhibits Aurora kinase, NF-κB and TGF-β signaling pathways in Jak2V617F mutant hematopoietic cells. Overall, our data suggest that Palbociclib in combination with Ruxolitinib may have therapeutic potential for treatment of MF.

2021-11-05 | GSE173814 | GEO

Human breast cancer biopsies of patients treated or not with the combination of palbociclib and fulvestrant

Project description:Metastatic HR+ HER2- breast cancer is an intractable disease that resists to the first-line treatment based on the combination of CDK4/6 inhibitor and hormone therapy (HT). To identify targets that further increase palbociclib-HT efficacy, we utilized biopsies from cancer patients who showed recurrence after treatment, HR+HER2- luminal cancer cells sensitive and resistant to the palbociclib-HT. Proteomic analysis of human samples revealed an upregulation of the oxidative stress-triggered proteasome subunit alpha7 (PSMA7) in metastatic relapses in different organs after patient's resistance to palbociclib-HT combination.

2025-05-07 | PXD053296 | Pride

Histone variants and modification in T-47D cells

Project description:To investigate the impact of histone variants and modification on gene regulation, we report high-throughput profiles of six histone markers, H2A.Z, H3K4me2, H3K9me3, H3K27me3, H3K27ac, and H3K36me3, by ChIP-Seq in T-47D breast cancer cells. Libraries were sequenced with the Illumina HiSeq 2000 analyzer for 50 bp paired-end reads and over 20 million uniquely aligned reads were collected for each histone marker. To examine the impact of histone modification on gene expression regulation in T-47D cells.

2016-04-06 | E-GEOD-63109 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data